Reperfusion after 4·5 hours reduces infarct growth and improves clinical outcomes

International Journal of Stroke

Volumn 9, Issue 3, 2014, Pages 266-269

  Picanço, Miguel R ^a   Christensen, Søren ^a   Campbell, Bruce C V ^a   Churilov, Leonid ^a   Parsons, Mark W ^b   Desmond, Patricia M ^a   Barber, P Alan ^c   Levi, Christopher R ^b   Bladin, Christopher F ^d   Donnan, Geoffrey A ^a   Davis, Stephen M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d MONASH UNIVERSITY   (Australia)

Author keywords

MRI; Stroke; Thrombolysis; tPA

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOUBLE BLIND PROCEDURE; ECHO PLANAR IMAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; REPERFUSION; TREATMENT INDICATION; VERY ELDERLY; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TPA; TREATMENT OUTCOME;

MRI; STROKE; THROMBOLYSIS; TPA;

AGED; AGED, 80 AND OVER; BRAIN INFARCTION; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPERFUSION; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84896313781     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12209     Document Type: Article

References (12)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
3. Lees KR, Bluhmki E, von Kummer R etal. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695-1703.
4. Sandercock P, Wardlaw JM, Lindley RI etal. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352-2363.
5. Ahmed N, Kellert L, Lees KR, Mikulik R, Tatlisumak T, Toni D. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the safe implementation of treatment in stroke international stroke thrombolysis register (SITS-ISTR): an observational study. JAMA Neurology 2013; 70:837-844.
6. Davis SM, Donnan GA, Parsons MW etal. Effects of alteplase beyond 3h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299-309.
7. Ebinger M, Christensen S, De Silva DA etal. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke 2009; 40:1353-1358.
8. Christensen S, Campbell BCV, Perez de la Ossa N etal. Optimal perfusion thresholds for prediction of tissue destined for infarction in the combined EPITHET and DEFUSE dataset. Stroke 2010; 41:e297.
9. Olivot JM, Mlynash M, Thijs VN etal. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke 2009; 40:469-475.
10. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke 2010; 41:2817-2821.
11. Wahlgren N, Ahmed N, Davalos A etal. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275-282.
12. Ma H, Parsons MW, Christensen S etal. A multicentre, randomized, double blinded, placebo controlled phase 3 study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012; 7:74-80.